923565-99-5

Usage

Uses

Used in Pharmaceutical Industry:
1-Cbz-(2R)-Methylpiperazine is used as a key intermediate in the synthesis of drugs for its ability to facilitate the creation of complex molecular structures. Its presence in the molecular composition allows for the development of new therapeutic agents with improved pharmacological properties.
Used in Bioactive Molecule Synthesis:
In the field of bioactive molecules, 1-Cbz-(2R)-Methylpiperazine is utilized as a versatile building block to enhance the biological activity of synthesized compounds. Its unique structure contributes to the potency and selectivity of these molecules, making it an essential component in medicinal chemistry.
Used in Agrochemical Production:
1-Cbz-(2R)-Methylpiperazine is employed as a crucial component in the development of agrochemicals, where it serves as a precursor to create molecules with pesticidal or herbicidal properties. Its role in these applications is to provide a stable and effective platform for the attachment of functional groups that target specific pests or weeds.
Used in Organic Compound Synthesis:
As a fundamental building block in organic chemistry, 1-Cbz-(2R)-Methylpiperazine is used in the synthesis of a wide range of organic compounds. Its structural features allow for the creation of diverse chemical entities with various applications, from materials science to specialty chemicals.

Upstream product

• 1163793-25-6 1-benzyl 4-(tert-butyl) (R)-2-methylpiperazine-1,4-dicarboxylate 
• 243982-41-4 (R)-3-methyl-1-((2-nitrophenyl)sulfonyl)piperazine 
• 501-53-1 benzyl chloroformate 
• 75336-86-6 (2R)-methylpiperazine 
• 1025927-13-2 (R)-2-Methyl-4-(2-nitro-benzenesulfonyl)-piperazine-1-carboxylic acid benzyl ester 

Downstream Products

• 923565-76-8 phenylmethyl (2R)-2-methyl-4-((4-(2-(methyloxy)-2-oxoethyl)phenyl)methyl)-1-piperazinecarboxylate 
• 942224-50-2 (R)-benzyl 4-(3-amino-2-fluorobenzyl)-2-methylpiperazine-1-carboxylate 

Relevant academic research and scientific papers

SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF

The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Secondary amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase

N'-Methyl-N-(4-tert-butyl-1,2,5,6-tetrahydropyridine)thiourea, SDZ048- 619 (1), is a modest inhibitor (IC50 = 180 μM) of pyruvate dehydrogenase kinase (PDHK). In an optimization of the N-methylcarbothioamide moiety of 1, it was discovered that amides with a small acyl group, in particular appropriately substituted amides of (R)-3,3,3-trifluoro-2-hydroxy-2- methylpropionic acid, are inhibitors of PDHK. Utilizing this acyl moiety, herein is reported the rationale leading to the optimization of a series of acylated piperazine derivatives. Methyl substitution of the piperazine at the 2- and 5-positions (with S and R absolute stereochemistry) markedly increased the potency of the lead compound (> 1000-fold). Oral bioavailability of the compounds in this series is good and is optimal (as measured by AUC) when the 4-position of the piperazine is substituted with an electron-poor benzoyl moiety. (+)-1-N-[2,5-(S,R)-Dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R)- 3,3,3-trifluoro-2-hydroxy-2-methylpropanamide (14e) inhibits PDHK in the primary enzymatic assay with an IC50 of 16 ± 2 nM, enhances the oxidation of [14C]lactate into 14CO2 in human fibroblasts with an EC50 of 57 ± 13 nM, diminishes lactate significantly 2.5 h post-oral-dose at doses as low as 1 μmol/kg, and increases the ex vivo activity of PDH in muscle, liver, and fat tissues in normal Sprague-Dawley rats. These PDHK inhibitors, however, do not lower glucose in diabetic animal models.